#5386 ONCO-NEPHROLOGY: THE ROLE OF KIDNEY BIOPSY IN THE MANAGEMENT OF SIDE EFFECTS OF TARGETED THERAPIES

Abstract Background and Aims The introduction of innovative therapies, resulting from revisiting cancer as a disease the immune system, has changed scenario complications. These new classes drugs, such targeted therapies checkpoint inhibitors, assure substantial advantages in therapy, despite some side affecting various organs, including kidney. Histological evaluations kidney disorders induced by targeted/immunotherapy are limited. Method In this study we examined histological features patients treated with agents who underwent biopsy for onset failure and/or urinary abnormalities. Results cohort included 30 adult patients. most frequently administered were immunotherapy (30%), therapy (26.7%), plus (13.3%), chemotherapy (16.7%). common finding was tubular interstitial nephritis (30%) that associated acute necrosis 4 cases, thrombotic microangiopathy (23.3%). After biopsy, 16 according to diagnosis. Fourteen steroids. One patient membranous nephropathy single dose rituximab. A severe requiring dialysis received treatment eculizumab 3 months. Overall renal response obtained all glucocorticoids, while complete achieved Cancer resumed without change 21 out Conclusion Kidney is critical management toxicities should be strongly encouraged showing adverse effects novel agents.